Press Releases

Eye Catching Stocks: Gilead Sciences Inc. (GILD), Halliburton Company (HAL), Morgan Stanley (MS)

istreetwire45

Gilead Sciences Inc. (GILD) continued its upward trend with the stock climbing 0.73% or $0.51 to close the day at $70.31 on active trading volume of 10.94M shares, compared to its three month average trading volume of 10.57M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -19.16%, compared to the industry which has advanced 0.84% over the same period. With RSI of 48.38, the stock should still continue to rise and get closer to its one year target estimate of $84.27, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Halliburton Company (HAL) fell -2.62% during last trading as the stock lost $-1.46 to finish the day at $54.31 with about 10.91M shares changing hands, compared to its three month average trading volume of 8.14M. The $47.54B market cap company, which fluctuated between $54.26 and $56 during the day, currently situated 88.77% above its 52 week low of $30.84 and -7.6% away from its one year high of $58.78. The RSI of 41.8 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company’s Completion and Production segment offers production enhancement services, including stimulation and sand control services; and cementing services, such as bonding the well, well casing, and casing equipment. It also provides completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, liner hanger systems, sand control systems, and service tools; pressure control services comprising coiled tubing, hydraulic workover units, and downhole tools; and pipeline and process services, such as pre-commissioning and maintenance, subsea pipeline, conventional pipeline, and process services. In addition, this segment offers oilfield production and completion chemicals and services; electrical submersible pumps and progressive cavity pumps; and installation, maintenance, repair, and testing services. The company’s Drilling and Evaluation segment provides drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; and drilling systems and services. It also offers wireline and perforating services, including open-hole logging, and cased-hole and slickline services; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. In addition, this segment offers integrated exploration, drilling, and production software, as well as related professional and data management services; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and oilfield project management and integrated solutions. Halliburton Company was founded in 1919 and is based in Houston, Texas.

Morgan Stanley (MS) saw its value decrease by -0.82% as the stock dropped $-0.38 to finish the day at a closing price of $46.11. The stock was lighter in trading and has fluctuated between $22.68-$46.75 per share for the past year. The shares, which traded within a range of $45.8 to $46.5 during the day, are up by 15.8% in the past three months and up by 53.43% over the past six months. It is currently trading 5.31% above its 20 day moving average and 6.74% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $47.38 a share over the next twelve months. The current relative strength index (RSI) reading is 63.68. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The company’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The company’s Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.

 

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *